林 建中

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Lung Neoplasms 89%
3. ErbB Receptors 81%
4. Mutation 61%
5. Adenocarcinoma of Lung 54%
6. Protein-Tyrosine Kinases 44%
7. Survival 41%
8. Genome-Wide Association Study 38%
9. Liquid Biopsy 32%
10. Smoking 31%
11. osimertinib 26%
12. Chronic Obstructive Pulmonary Disease 24%
13. Saliva 22%
14. capmatinib 21%
15. Neoplasms 20%
16. Gefitinib 17%
17. trametinib 16%
18. Drug Therapy 16%
19. Malignant Pleural Effusion 15%
20. Therapeutics 15%
21. Afatinib 14%
22. Lung 13%
23. Propensity Score 12%
24. Bronchodilator Agents 11%
25. Brain 11%
26. Confidence Intervals 10%
27. Erlotinib Hydrochloride 9%
28. pembrolizumab 9%
29. Biomarkers 8%
30. Quality of Life 8%
31. Cohort Studies 8%
32. Pneumonia 8%
33. Mendelian Randomization Analysis 8%
34. bactericidal permeability increasing protein 8%
35. Ligands 8%
36. Crizotinib 8%
37. Transketolase 8%
38. Obstructive Lung Diseases 7%
39. AMP-activated protein kinase kinase 7%
40. angiotensin converting enzyme 2 7%
41. Peptide Nucleic Acids 7%